Immunotherapies targeting immune checkpoints, such as programmed cell death protein 1 (PD-1)/ programmed cell death 1 ligand 1 (PD-L1)/ programmed cell death 1 ligand 2 (PD-L2), have shown promising prospects for treating OSCC and melanoma 5, 6. Here, PDCD1 is linked to melanoma.